Symphogen is leading the development of antibody mixture therapeutics to improve the treatment of serious human diseases. Symphogen’s growing pipeline of cancer programs reflect a new approach to fighting cancer with unique mechanisms based on multiple simultaneous attacks on tumors. The result is improved efficacy and the potential to reduce the development of drug resistance.
